InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures
InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR
- Milestone
- FDA approval
- Indication
- transcarotid artery revascularization (TCAR) procedures
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The approval expands the company's product portfolio and market size, likely prompting a positive stock reaction.
Market read
Regulatory clearance is a material catalyst for a medical‑device microcap, offering a clear near‑term trade idea.
What to watch
Reimbursement rates and competition from established carotid stent manufacturers could temper revenue expansion.
Background
InspireMD filed an 8‑K announcing FDA approval of its CGuard® Prime TransCarotid Stent System for TCAR procedures.
Ticker impact
FDA approved InspireMD's CGuard® Prime TransCarotid Stent, expanding its addressable market to over 35,000 TCAR procedures annually.
upward pressure as investors price in expanded market opportunity and strong trial data.
The approval doubles the platform's addressable market, backed by 100% acute device success and no adverse events in the pivotal trial.
Market effects
Strengthens the carotid stent and neurovascular device sector, potentially boosting peers with similar technologies.
Adds to U.S. medical device innovation pipeline, may attract regional hospital procurement interest.
Sets a precedent for transcarotid solutions worldwide, could influence global regulatory expectations.
Counterpoint
If adoption is slower than projected, the market may already price in optimistic growth, limiting upside.
Key entities
- companyInspireMD, Inc.
Developer of the CGuard® Prime carotid stent system.
- regulatorFDA
U.S. Food and Drug Administration granting the approval.


